Treatments

These posts deal with some the possible treatments for prostate cancer.

Home » Treatments

Focal Therapy – New pain-free treatment for prostate cancer? Not quite

If you or someone close to you has lived with prostate cancer, you’ve probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the “new pain-free treatment for prostate cancer”. But don’t hold your breath; it’s still in its experimental phases. This is a warning that focal therapy is still experimental and should be considered only in a clinical trial setting.  Read the article.

Focal Therapy – New pain-free treatment for prostate cancer? Not quite Read More »

VIDEO: Dr. Robert Hamilton, “Hormones, hormone therapy and prostate cancer”

July 2013 Scotiabank Awareness Night “Hormones, hormone therapy and prostate cancer”       Dr. Robert J Hamilton MD, MPH, FRCSC  Surgical Oncologist, The Princess Margaret University Health Network  Assistant Professor, Dept. of Surgery (Urology), University of Toronto Testosterone and related hormones that together we call “androgens” play a role in every aspect of prostate cancer…from reducing chances of being diagnosed with prostate cancer, reducing progression of low risk prostate cancer, as an additive to radiation therapy, to suppressing growth in patients with advanced cancers. Dr. Hamilton presents the role of androgens and hormone therapy across the landscape of prostate

VIDEO: Dr. Robert Hamilton, “Hormones, hormone therapy and prostate cancer” Read More »

5 Ways to Prevent Unnecessary Treatment for Prostate Cancer

Now that the government panels and medical associations no longer recommend PSA testing, consider this: in the 1980s, before PSA testing, 50,000 men died annually from prostate cancer. In the 1990s, with PSA testing, 30,000 died annually. PSA testing saved 20,000 men each year (about 25,000 now) from slow, painful deaths from prostate cancer. And they are telling us to stop doing this test? Consider: 50,000 prostatectomies are performed each year for prostate cancer, yet 40,000 of these surgeries are unnecessary. The numbers are similar for radiation therapy. This is why mainstream medicine has retreated from routine PSA testing. Retreating

5 Ways to Prevent Unnecessary Treatment for Prostate Cancer Read More »

Active surveillance may miss aggressive prostate cancers in black men

A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.  Although prior studies have found it safe to delay treatment and monitor some presumably slow-growing or low-risk prostate cancers, such “active surveillance” (AS) does not appear to be a good idea for black men, the study concludes. Read the article.

Active surveillance may miss aggressive prostate cancers in black men Read More »

VIDEO: Dr. Saibish “The current role of Brachytherapy”

      May 2013 Scotiabank Awateness Night Dr. Saibishkumar Elantholi Parameswaran, “Dr. Saibish” MBBS, MD, FRCPC Assistant Professor,  Department of Radiation Oncology, University of TorontoRadiation Oncologist, The Princess Margaret University Health Network “Prostate cancer treatment: the current role of Brachytherapy” In early-stage prostate cancer, brachytherapy has a proven performance that is on a par with benchmark prostate cancer treatments such as the radical prostatectomy.The indications for use of this approach are expanding, and modifications in brachytherapy techniques have resulted in improvement in tumour-related outcomes along with better quality of life and convenience for patients with prostate cancer.This presentation details the evolution

VIDEO: Dr. Saibish “The current role of Brachytherapy” Read More »

Brachytherapy a Good Option for Younger Prostate Cancer Patients

Brachytherapy (BT) provides excellent long-term outcomes for relatively young men with clinically localized prostate cancer (PCa), researchers reported. In a study of 236 men aged 60 years or younger with clinically localized PCa, BT alone or in combination with external beam radiation therapy (EBRT) was associated with eight-year PSA relapse-free survival (RFS), cancer-specific survival, and overall survival rates of 96%, 99%, and 96%, respectively, according to findings published in BJU International (2013;111:1231-1236). BT-based approaches also were associated with a low risk of long-term genitourinary (GI) and gastrointestinal (GI) morbidities, with erectile function preserved in more than half of patients. Read

Brachytherapy a Good Option for Younger Prostate Cancer Patients Read More »

Prostate Cancer AS May Be OK Despite Higher PSA

Active surveillance (AS) may be an appropriate management option in carefully selected prostate cancer (PCa) patients with a baseline PSA level of 10 ng/mL or higher, according to study findings presented at the American Urological Association annual meeting. The study showed that these patients are no more likely to experience pathologic progression that patients with lower PSA levels at baseline. Read the article.

Prostate Cancer AS May Be OK Despite Higher PSA Read More »

Focal Therapy for Prostate Cancer Advances

Laser ablation, cryotherapy, and hemiablative brachytherapy are among the novel approaches that show promise for the focal treatment of localized prostate cancer (PCa), according to studies presented at the 28th annual congress of the European Association of Urology. Most of these treatments are performed under magnetic resonance imaging (MRI) guidance. Read the article.

Focal Therapy for Prostate Cancer Advances Read More »

Scroll to Top